Suptavumab: A Deep Dive into the REGN2222 Monoclonal Antibody REGN2222 is a engineered immunoglobulin developed to selectively inhibit IL-18 , a important cytokine associated in acute respiratory https://www.targetmol.com/compound/suptavumab